Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03949244 · ClinicalTrials.gov registry record · Phase 4
Nailfold Capillary Blood Flow With Latanoprost Bunod
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
NCT03949244: Completed Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03949244 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 47 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03949244, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the movement of blood in small blood vessels. It is simple, safe and does not penetrate the skin. The skin fold that is at the tip of the finger is called the "nailfold". NFC has been used to assess blood vessel narrowing in patients with glaucoma.
Primary Outcome
NFC blood flow at baseline and at 15 minutes after NF application to the 4th digit of the nondominant hand.
Interventions
- DRUG Latanoprost 0.005%
- DRUG Latanoprost bunod 0.024%
- DRUG Normal saline 0.9%
- DIAGNOSTIC_TEST Nailfold capillaroscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 4 |
What the finished NCT03949244 record still lists
NCT03949244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 4 interventions - of which Latanoprost 0.005% is the first listed.
NCT03949244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03949244 about?
NCT03949244 is a clinical study titled "Nailfold Capillary Blood Flow With Latanoprost Bunod". The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the...
What is the current status of trial NCT03949244?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2019-08-15. Estimated completion is 2020-10-01.
What interventions are being tested in trial NCT03949244?
The interventions under investigation include: Latanoprost 0.005% (DRUG), Latanoprost bunod 0.024% (DRUG), Normal saline 0.9% (DRUG), Nailfold capillaroscopy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03949244?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03949244's enrollment target sits among peer trials
47 1348th of 2000 higher than 653 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI